Literature DB >> 6091291

Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage.

F Laghi Pasini, A L Pasqui, L Ceccatelli, P L Capecchi, A Orrico, T Di Perri.   

Abstract

The "in vitro" effects of heparin on different functions of human polymorphonuclear leukocytes were studied. Granulocyte aggregation, enzyme release induced by FMLP and zymosan-activated serum and superoxide anion and chemiluminescence generated by FMLP were assessed. Heparin (25-500 micrograms/ml) was able to inhibit in a dose-dependent way cellular aggregation and degranulation induced either by FMLP or by zymosan-activated serum. FMLP-dependent superoxide anion generation and chemiluminescence were specifically inhibited by heparin at the concentration of 25 micrograms/ml. Our results showed that heparin "in vitro" inhibits all the aspects of the functional and metabolic granulocyte activation. A possible protecting effect of the drug on leukocyte-mediated tissue injury and vascular damage is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091291     DOI: 10.1016/0049-3848(84)90284-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration.

Authors:  T DiPerri; F L Pasini; C Frigerio; P Blardi; F Centini; G L Messa; A Ghezzi; L Volpi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Inhibition of leucocyte elastase by heparin and its derivatives.

Authors:  F Redini; J M Tixier; M Petitou; J Choay; L Robert; W Hornebeck
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

4.  Captopril: a free radical scavenger.

Authors:  M Chopra; N Scott; J McMurray; J McLay; A Bridges; W E Smith; J J Belch
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

5.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30

6.  Protective role of heparin in the injury of the liver and kidney on the experimental model of ischemia/reperfusion.

Authors:  Ali Ümit Yener; Mustafa Cüneyt Çiçek; Serhat Bahadır Genç; Turgut Özkan; Emre Doğan; Bülent Cağlar Bilgin; Tezcan Akın; Havva Erdem; Handan Ankarali
Journal:  J Cardiothorac Surg       Date:  2014-02-17       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.